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David M. Livermore 
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Rates of enzyme-mediated catalysis are proportional to enzyme quantity, so increasing the amount of p-lactamase 
should increase resistance. Kinetic considerations support this argument for both Gram-positive and Gram-negative 
bacteria. 
Direct relationships between resistance and enzyme quantity are most obvious with constitutive fi-lactamases, e.g. 
the TEM types from Gram-negative bacteria. As the level of TEM enzyme rises, so do the MlCs of substrates and the 
concentrations of inhibitors required to  potentiate these substrates. The position is more complex for inducible 
p-lactamases, e.g. the AmpC types of Enterobacter spp., Citrobacter freundii, Serratia spp. and Pseudomonas 
aeruginosa. Third-generation cephalosporins are labile to these enzymes, but are only weak inducers, so the 
p-lactamase-inducible strains appear susceptible. Once, however, the enzyme is derepressed, resistance is apparent. The 
behavior of inhibitor combinations against inducible p-lactamases is complicated by the propensity of some inhibitors 
to  induce further enzyme synthesis. 
As the inoculum is raised in laboratory tests, the amount of p-lactamase and MlCs also rise. This is notorious for 
staphylococci but is seen also for some Gram-negative organisms, notably klebsiellae with extended-spectrum 
p-lactamases. A p-lactamase-related inoculum effect generally predicts clinical failure. 
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INTRODUCTION 
Numerous excellent reviews on b-lactamases stress 
which compounds particular enzymes can hydrolyze 
(eg. Bush et a1 [l]). This review, however, will have 
a different emphasis, concentrating on 0-lactamase 
quantity as a crucial determinant of the levels of 
resistance seen in clinical isolates. The role of 
0-lactamase quantity will be considered from three 
standpoints. First, the interplay of 0-lactamase quantity 
with the enzyme’s location and kinetics will be 
discussed at a theoretical and mathematical level. 
Second, direct studies relating levels of enzyme to 
levels of resistance will be considered, not only for 
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constitutively expressed (3-lactamases but also for 
inducible types and those encoded by genes that 
commonly are silent. Finally inoculum effects will be 
discussed in so far as they relate to the amounts of (3- 
lactamase present in routine susceptibility tests. 
INTERPLAY OF p-LACTAMASE QUANTITY, LOCATION 
AND KINETICS 
The activities of most p-lactamases, like those of other 
enzymes, can be described by the Michaelis-Menten 
equation, which relates reaction velocity (antibiotic 
hydrolysis rate, V) to substrate (antibiotic) concen- 
tration ( S ) ,  thus: 
S V= v,,, ~ 
KM + S 
where I/,,,, is the maximum reaction rate, achieved 
when the enzyme is saturated with substrate, and the 
KM, or Michaelis constant, is an inverse measure of 
enzyme-substrate affinity, being the substrate concen- 
tration that allows the enzyme to function at 50% of 
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K,,,4x. Kll'lx itself is a composite parameter, equivalent to 
the amount of enzyme multiplied by the maximum 
number of catalytic events (hydrolyses of p-lactam 
molecules) that each enzyme molecule can achieve per 
unit of time. 
From these relationships it is apparent that doub- 
ling (say) the amount of P-lactamase should double the 
rate a t  which the drug is hydrolyzed, thereby increasing 
the level of resistance engendered by the enzyme. 
However, a complexity arises in relation to the location 
of the (j-lactarnase. Like other microbial proteins, 
p-lactamases are made in the cytoplasm and then 
transported across the cytoplasmic membrane. In the 
case of the Gram-positive cell, all that lies beyond the 
cytoplasmic membrane is the peptidoglycan layer and, 
maybe, capsular material (Figure 1). p-Lactamases niay 
either electrostatically adhere to these layers or diffuse 
away into the extracellular milieu. In  either case, 
however, the p-lactamase is essentially extracellular. 
The situation is very different in Gram-negative 
bacteria, where the (J-lactamase remains largely in the 
periplasm, between the outer and cytoplasmic mem- 
branes (Figure I), and where its ability to protect the 
bacteria is contingent also on the permeability barrier 
afforded by the outer membrane [2]. 
The extracellular p-lactamases of Gram-positive 
species act to reduce the environmental p-lactam 
concentration (So)  until it falls below what the MIC 
would be if the organism did not have the (3-lactamase 
(S+).  Then, and only then, does bacterial growth begin. 
The period ( t )  required to achieve this reduction in 
drug concentration is predictable with good accuracy 
[3,4] from an integrated form of the Michaelis- 
Menten equation: 
[ K M  (log, s, - log, S+) + (S" - S,)] 
t =  (2) 
V,,,.,, 
Critically, t is inversely proportional to V,,,,,, and, 
therefore, to the amount of enzyme: the more 
p-lactaniase is present, the quicker the drug concen- 
tration is reduced to a tolerable level. The importance 
of enzyme quantity is thus apparent; moreover, the 
enzyme quantity is directly proportional to the number 
of cells. This becomes critical when, later in this review, 
inoculum effects are considered. 
In Gram-negative bacteria the drug diffuses across 
the outer membrane via the pores formed by porin 
proteins. Its rate of diffusion obeys Fick's law, which 
states that the rate of influx (V) is equivalent to a 
permeability constant (C) multiplied by the concen- 
tration difference of drug across the nienibrane, where 
S,, and S,, are the external and periplasniic drug con- 
centrations, respectively: 
Drug destruction within the periplasm again follows 
the Michaelis-Menten equation (equation 1) and K,,, 
is proportional to the quantity of enzyme. A balance is 
established between uptake and destruction of the drug, 
such that Vin equation 1 equals Vin equation 3, and 
the periplasniic drug concentration stabilizes at a 
steady-state (constant) level as described in equation 4 
[51: 
The more enzyme that is present, the lower the steady- 
state S,, will be, and the less likely it is that the 
penicillin-binding proteins will be poisoned. So, as 
with Gram-positive bacteria, there is close interplay 
between (3-lactamase kinetics, location and-the 
particular topic of this review-quantity. The mathe- 
matical representation given in equation 4 can be used 
Figure 1 Location of (3-lactamases (shaded circles) in Gram-positive and Gram-negative bacteria. 
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to predict MICs, with reasonable accuracy, &om kinetic 
and permeability data for enterobacteria (but not 
Pseudornonas) [5,6]. 
DIRECT STUDIES ON P-LACTAMASE QUANTITY AND 
RESISTANCE 
So much for the theory: next it is appropriate to 
consider experimental studies relating the level of 
resistance to the amount of enzyme. Three cases will 
be considered: first, when a 6-lactamase is expressed 
constitutively; second, when it is inducible; and third, 
where it is coded by a silent gene (one which is not 
usually expressed). 
Constitutive p-lactamases present the simplest case. 
Examples include all the common plasmid-medated p- 
lactamases of Gram-negative rods and the chromosomal 
enzymes of klebsiellae and Bacteroides spp. [1,2]. TEM-1 
is by far the commonest plasmidic p-lactamase in 
Gram-negative species, being responsible for 90% of 
the ampicillin resistance seen in Escherichia coli isolates 
[2,7]. The enzyme destroys ampicillin, piperacillin 
and cefoperazone, but not other third-generation 
cephalosporins [1,2]. Its amount varies at least 150-fold 
l o  O o o 1  
amongst strains [8-lo], reflecting the number ofplasmid 
copies per cell, the degree of gene amplification within 
plasmids or transposons [l  13 and, perhaps, the promoter 
efficiency. The effects of variation in enzyme quantity 
are illustrated in Figure 2a, which shows MICs for 36 
E. coli isolates with TEM-1 p-lactamase and no other 
defeflses against p-lactams, graded into four groups 
according to p-lactamase-specific activity. For each of 
the three substrates shown-ampicillin, piperacillin and 
cefoperazone-the level of resistance increased with 
the level of p-lactamase, whereas MICs of cefuroxime, 
which is stable to TEM-1 enzyme, were independent 
of the quantity of enzyme. 
Analogous effects are seen for 6-lactamase-inhibitor 
combinations, and Figure 2b shows, for the same 36 
E. coli isolates, the mean concentration of inhibitors 
required to potentiate various penicillins to their 
accepted breakpoints. As the level of p-lactamase 
activity increased, there was an increase in the amount 
of sulbactam needed to bring ampicillin MICs down to 
8 mg/L. Similarly, more clavulanate was needed to 
reduce amoxicillin MICs to 8 mg/L and more tazo- 
bactam was needed to reduce piperacillin MICs to 
16 mg/L [9,12,13]. Recent studies indicate that 
1' 
0.1 - 0.31 - 1.01 - 23.01 
0.3 1.0 3.0 
Specific activity (pmoles penicillin G hydrolyzed/min/mg protein) 
Figure 2 Quantity of TEM-1 p-lactamase and levels of resistance for 36 Escherichia coli isolates. Data are reworked from 
Seetulsingh et a l  [9], Livermore and Seetulsingh [12] and Livermore [13]. The isolates are grouped accordmg to p-lactamase 
specific activity. (A) The geometric mean MICs of: 0, ampicillin; 0, piperacillin; A ,  cefoperazone; and A, cefuroxime. 
(B) The mean concentrations required to potentiate penicillin MICs to breakpoint as follows: H, sulbactam to reduce 
ampican MICs to 8 mg/L; A ,  clavulanate to reduce amoxicihn MICs to 8 mg/L; and 0, tazobactam to reduce piperacillin 
MICs to 16 mg/L. 
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variation in enzyme quantity was the reason why, even 
within a single strain outbreak, some Klebsiella pneu- 
moniae were resistant to piperacillin/tazobactam whereas 
others were susceptible [14]. 
The situation becomes more complex when we 
consider inducible (3-lactamases. The two most im- 
portant groups of inducible (3-lactaniases, from the 
clinician's perspective, are first the chromosomal AmpC 
(Bush Group 1) P-lactamases in Enterobacter spp., 
Cifrobacterjieundii, Sewatid spp., Mozanella morganii and 
Pseudomoms aertqinosa, and second, staphylococcal 
penicillinase, which is now produced by over 90% of 
staphylococci [1,2,7]. Other inducible p-lactamases 
include the molecular class A chromosomal enzymes of 
Citrobactev diversus and Proteus vulgaris, which, unlike 
AmpC 6-lactamases, are inhibited by clavulanate [1,2], 
and also the enzymes of Stenotrophomorias rnaltophilia. 
This species has two inducible p-lactamases, L1 and L2, 
both of which are chromosomal and controlled by the 
same regulatory system [15,16]. L1 is a penicillinase that 
also attacks carbapenems, whereas L2 is predominantly 
a cephalosporinase. 
Whenever a (3-lactamase is inducible, its ability to 
confer resistance depends both on its hydrolytic activity 
and on the amount of enzyme synthesis that a particular 
compound induces. This is conveniently illustrated by 
comparing MICs for isogenic mutant series that vary 
only in p-lactamase inducibility [17-201. Table 1 shows 
such data for an Enterobactev series, comprising first the 
parent strain, where the AmpC enzyme was inducible, 
a mutant where the enzyme had become derepressed 
(i.e. made at a constant high level even when no 
(3-lactam was present), and, finally, a (3-lactamase- 
deficient mutant, which made only a trace level of 
enzyme irrespective of the presence of l3-lactams. 
Cephaloridine and ampicihn, the first two conipounds 
considered in Table 1, are strong inducers below the 
MIC and are destroyed by the enzyme. This behavior 
is reflected in their MICs; both the inducible strain and 
its derepressed mutant are similarly resistant to the 
compounds, whereas the (3-lactamase-deficient mutant 
is considerably more susceptible 11 81. The reasons why 
compounds are strong or weak inducers of AmpC 
enzymes remain unclear, although the genetic bases of 
induction and derepression are now understood. These 
are reviewed in an accompanying paper [Medeiros, this 
supplement], while a fuller account is to be found in 
Jacobs et a1 [21]. 
Piperacillin is about as labile as ampicillin, as 
illustrated by the V,,,,, and KM data. The third- 
generation cephalosporins cefotaxime and ceftazidime, 
and also aztreonam, can be destroyed by the enzyme, 
albeit more slowly than the aminopenicillins [ 19,201. 
However, all these compounds are much weaker 
inducers than ampicillin. Critically, they do not induce 
enzyme synthesis below the MIC; thus their MICs for 
the a-lactarnase-inducible organism are as low as for the 
(3-lactaniase-deficient mutant. When, however, the 
(3-lactamase is made at a high level without induction, 
as in the derepressed mutant (where the enzyme 
Table 1 Abllity of the AmpC p-lactamase of Enteuobactev cloacae to confer resistance to B-lactams, in relation to their inducer 
power and lability 
MlCs (nig/L) for E cloaca? 684 with 
AnipC (3-lactamase' Hydrol) $15 
K,,, (v$ Kv ( P W  Inducible I>crepreised B d  Inducer power" 
Cephaloridine >512 >512 4 ++ 100 6 10 
Ampicillin 256 512 2 + 0.2.5 4 
Piperacillin 2 04 2 - (1. 15 33 
Cefo taximc 0.06 256 0.06 - 0.2 44 
Ccftazidime 0.12 04 0.06 0.005 8 
Aztreonaiii 0.03 32 0.015 - NII N 11 
Meropeneni 0.03 0.03 0.03 f !  0.005~ NI> 
- 
Imipeneni 0.25 0.25 0.12 ++ < 0.0 I N D  
0.0004' 
'Data from Ymg et a1 [IX], Ydng arid Livermore [19] and Chen and Livermore [20], obtained with inocula of 10' colony-forming 
unitdspot. 
"Inducer power: -, negligible p-lactamase induction below MIC; +, 10-100-fold p-lactaniase induction below MI(:; ++, > 100-fdd 
fi-lactaiiiase induction helow MIC; +!, somc induction below MIC hut assays distorted by p-lactamase inactivation. 
'Cephdoridine = 100%. Data from Yang et a1 [I  81, Yang and Livermore 1191 and Chen and Livermore [20]. 
dInitial hydrolysis rate. 
'Steady-state rate once equilibrium established between activated and deactivated forms of the enzyme (see Yang and Livermore [19\). 
MIC, minimum inhibitory concentration; V,,,,,,, maximum rate of antibiotic hydrolysis; K,, Michaelis constant (uhqtrate concentration that 
allow? the enzyme to function at 50% of V,,lax); ND, not determined. 
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accounts for 3% of total cell protein), there is substantial 
resistance to piperacillin and the third-generation 
cephalosporins. As is now widely recognized, this 
behavior is these compounds’ Achilles heel: fi-lactarnase- 
inducible Enterobacter, Citrobacter freundi i  and Serratia 
strains spontaneously segregate derepressed mutants, 
which can be selected during cephalosporin therapy, 
leading to clinical failure [22]. This risk is about 20% 
when third-generation cephalosporins are used in the 
therapy of Enterobacter bacteraemia [23], even higher 
in pneumonia though minimal in urinary tract 
infection, where very high cephalosporin levels are 
attained [7]. Once selected, the mutants can accumulate 
in the hospital. In many countries, upwards of 30-40% 
of Enterobacter and Citrobacter freundi i  isolates are now 
derepressed at first isolation and so are broadly resistant 
to third-generation cephalosporins and to ureido- 
penicillins [2,7,24,25]. 
Regarding the carbapenems, imipenem is a very 
strong inducer of the Enterobactev AmpC enzyme and is 
hydrolyzed much more slowly than even the third- 
generation cephalosporins [18]. Meropenem is rather 
harder to examine and categorize, because it has a 
capacity to poison the enzyme as well as to induce it 
[19]. For both compounds, however, it does not matter 
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how, or whether, the enzyme is produced-the MIC 
remains equally low. 
Greater complexity arises when we consider the 
interaction of inhibitors and inducible p-lactamases 
because a compound may induce a p-lactamase as well 
as inhibit it, thereby partly negating its own inhibitory 
power. To illustrate this point, Figure 3 shows the 
distribution of inhibition zones of piperacillin 75 pg 
and piperacillin 75 pg + tazobactam 10 pg disks for 
1640 methicillin-susceptible Staphylococcus aureus isolates 
[26]. The zones of the piperacillin disks form a bimodal 
distribution, with a major peak-modal zone 18 mm 
-comprising rJ-lactamase-producing, piperacillin- 
resistant organisms, and a minor peak-modal zone 
38 mm-comprising piperacillin-susceptible, fi-lacta- 
mase-negative isolates [26]. Tazobactam is a good 
inhibitor of staphylococcal penicillinase in vitro and 
might be expected to make the fi-lactamase producers 
as susceptible as the non-producers to piperacillin 
[ 1,271. However, the modal zone of piperacillid 
tazobactam disks for the @-lactamase producers is only 
about 26 mm, whereas that for the non-producers 
remains around 38 mm. Thus, in these disk tests, 
tazobactam achieves a very incomplete reversal of 
the piperacillin resistance (for further details see Chen 
17 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 121314 
Zone (mm) 
Figure 3 Inhbition zone diameters of piperacdhn 75 pg (hatched columns) and piperacan 75 pg + tazobactam 10 pg 
(filled columns) disks for 1640 methicdlin-sensitive Stuphy~ococcus uureus isolates. Reprinted fiom Journal of Antimicrobial 
Chemotherapy, 32, Chen HY, Bonfigho G, M e n  M, et a1 Multicentre survey of the in-vitro activity of piperacilhn/ 
tazobactam against bacteria from hospitahzed patients in the British Isles, 24746,  1993, by permission of W.B. Saunders 
Company Ltd, London [26]. 
L i v e r m o r e :  (3-Lactamases:  q u a n t i t y  a n d  r e s i s t a n c e  4 5 1 5  
these data is uncertain; available evidence suggests that 
piperacillin/tazobactani gives adequate cover against 
staphylococcal infections. Nevertheless, the experi- 
ment serves to illustrate the difficulties of inhibiting 
an inducible 0-lactaniase. Another case where a 
(j-lactaniase inhibitor may act as a n  inducer concerns 
clavulanate with the AmpC (j-lactarnase of some 
enterobacteria, especially Moryanella nzoxmiii and 
Enterobactev cloacae. Clavulanate has Inininla1 ability to 
inhibit these enzymes but can induce their synthesis, 
with the result that it is prone, albeit weakly, to 
antagonize ticarcillin-itself labile but a weak inducer 
against (3-lactamase-inducible strains 1291. 
The final mode of production to mention is the 
condition where a strain carries a silent fi-lactainase 
gene. Only one good example exists: the Bacteroidcs 
CcrA carbapenemase, also known as the CfiA enzyme. 
The encoding gene, ccrA, occurs in 2-30/0 of Bacteroidcs 
.f.lXilis strains worldwide, but only a third to a half of 
these produce the enzyme [30] .  Enzyme expression, 
and its contingent resistance, demands migration of 
an  insertion sequence to a position upstream of the 
(3-lactamase structural gene [31,32]. Curiously, the 
necessary insertion sequence is only found in the sniall 
nlinority of Bactevoidesfragilis isolates that have the ccvA 
gene, but the basis of this association is unclear. Until 
this migration occurs, the (j-lactamase gene is silent. 
Once migration has occurred, the enzyme is produced 
copiously and the isolate is resistant to all available 
f3-lactams. 
A second (3-lactamase gene which, perhaps, may 
sometimes be silent is b / a r , ~ p . l ,  which codes for a 
carbapeneniase that is increasingly found in Gram- 
negative rods in Japan. Senda et a1 [33] found the gene 
in 15 of a collection of 3700 Pseudomonar aeru'qinosa 
isolates, but six of these remained susceptible to i m -  
penem and nieropenem at 54 mg/L, whilst the others 
were highly resistant (MIC 232 mg/L). It is not, 
however, clear whether the gene was silent in the 
carbapenem-susceptible isolates or whether the resistant 
isolates had some supplementary mechanism, such as 
impermeability. 
Figure 4 Induction of staphylococcal 13-lactaniase by 
tazobactani. Plates were seeded with staphylococci and a 
disk containing tazobactam 10 pg was applied. After 
overnight growth, the plates were overlaid with agar 
containing a starch-iodine-penicillin mixture. Where there 
was active fi-lactanme the penicillin was hydrolyzed to 
penicilloate, which reduced and decolorized the iodine. 
The strain in (A) had the A subtype of  penicillinase, and 
that in (B) had the C subtype. In each case, there was 
considerable enzyme activity around the disk, surrounded 
by a region with less activity. This is explicable only if 
tazobactani induces enzyme. Reprinted from Journal of 
Antimicrobial Chemotherapy, 32, Bonfiglio G, Livermore 
DM. Behaviour of P-lactamase-positive and -negative 
Stuplzylomccrrr aweris isolates in susceptibility tests with 
piperacilldtazobactam and other p-lactarnip-lactamase 
inhibitor combinations, 431-44, 1993, by permission of 
W.B. Saunders Company Ltd, London [28]. 
et a1 [26] and Bonfiglio and Livermore [27,28]). To 
investigate whether this might reflect induction 
of further (j-lactamase by tazobactani, plates were 
seeded with staphylococci, and disks containing tazo- 
bactani alone, without any piperacillin. were applied. 
After overnight growth, the tazobactam disks produced 
no inhibition zones, and the plates were flooded with 
a mixture of penicillin and iodine that detected 
fl-lactamase activity. Where (3-lactamase was present, 
the penicillin was hydrolyzed to penicilloate, which 
reduced the iodine to iodide, thereby decolorizing it. 
As a result, where the plate (Figure 4) looks clear there 
is (3-lactamase, and where it remains black, either there 
is no (3-lactamase, or it is inhibited. Among 80 
(3-lactaniase-positive isolates studied using this method, 
we saw two reaction patterns, one associated with 
subtype A (j-lactamase [2X] and the other with subtype 
C. The distinction between these is not relevant to the 
present review; the critical point is that in both patterns 
there was considerable 0-lactamase activity around the 
inhibitor disk, surrounded by an area where the 
enzyme was absent or inhibited. The only explanation 
is that, around the disk, tazobactam was inducing so 
much enzyme that the inhibition was overwhelmed. 
It should be stressed that the clinical significance of 
INOCULUM EFFECTS AS MANIFESTATIONS OF 
P-LACTAMASE QUANTITY 
The amount of @-lactamase initially prerent in labora- 
tory susceptibility tests depends on the inoculum, and, 
consequently, MICs are prone to rise as the inoculum 
is increased. The classic case is Staphylococcus uureus: as 
more 0-lactamase-positive staphylococci are added to 
an MIC test, they can destroy a greater amount of 
substrate in a given time (see equation 2) and so the 
MIC is raised. Benzylpenicifin is a very good substrate 
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Table 2 Inoculum effects for Staphylococcus aureus 
Geometric mean MIC (nig/L) 
P-Lactaniase positive (n= 80) b-Lactamaae negative (n=20) 
104 10" 1 0 4  106 v,,,, (%) Kh4 (PM) 
Penicillin G 14.1 128 0.09 0.17 100 12.3 
Methicillin 3.4 4.1 2.3 3.0 3 18 000 
Cephaloridine 0.18 2.3 0.05 0.06 0.18 0.05 
MIC data from Borifiglio and Livermore [28]; kinetic data from Hamilton-Miller [3] and Hamilton-Miller and Ramsay [4]. 
MIC, minirnuin inhibitory concentration; n, number of organisms; V,,,,,,, niaxirnuni rate of antibiotic hydrolysis; KM, Michaelis constant 
(substrate concentration that allows the enzyme to function at 50% of 
Table 3 Activity of p-lactams in vitro and in an intra-abdominal abscess model in rats versus Klebsiella pneumoniae with 
TEM-26 P-lactamase 
Broth MIC (nig/L) dt  inoculuin of 
Mean log CFU/g abscess 
10' i 07 Serum drug level (ing/L).' fluid at day 3h 
- - - Control 8.02 
Cefotaxime 1 256 17.8 7.26 
Cefpirome 1 >256 28.3 7.80 
CefOperdZOne 2 256 13.5 7.26 
Cefoperazone-sulbactam 0.5 256 8.9 5.84 
Cefiazidime 256 >256 19.4 8.85 
Iniipenem 0.5 16 7.1 4.99 
Data from Rice et a1 [ 3 7 ] .  
'Drug level achieved by continuous infusion. 
bRdt s  were killed after 3 days of treatment and bacteria per grain of abscess Ruid were counted. 
MIC, minimum inhibitory concentration; CFU, colony-forming units 
for staphylococcal penicillinase [34] and its MICs for 
p-lactamase producers increase almost 10-fold as the 
inoculum is raised from lo4 to lo6 (Table 2), whereas 
there is no analogous increase in MICs for p-lactamase- 
negative isolates [28]. Even for cephaloridine, which is 
not as readily hydrolyzed (lower I/,,,, although with 
high affinity as indicated by a low KM),  there is still a 
substantial (10-fold) inoculum effect for the enzyme 
producers, whereas with methicillin, which is genuinely 
stable because of low affinity (very high KM),  there is 
essentially no inoculum effect [28,34]. 
In theory, P-lactamase-related inoculum effects 
ought not to occur for Gram-negative bacteria, since 
their enzymes protect the individual cell and not, like 
those of the staphylococci, the culture as a whole (see 
equation 4 and Nikaido and Normark [6]). Never- 
theless, in practice, inoculum effects are seen with 
Gram-negative p-lactamase producers and, where pre- 
sent, generally indicate that the compound is unlikely 
to be effective. Examples where P-lactamase lability 
only becomes apparent with high inocula (106-107 
CFU/spot on agar or per mL of broth) include 
ampicillin against Moraxella catarrhalis with BRO-1 or 
BRO-2 enzymes [35], first-generation cephalosporins 
(e.g. cephalothin) against enterobacteria with classical 
TEM-1 or -2 p-lactamase [36] and, most topically, 
third-generation cephalosporins against enterobacteria 
with extended-spectrum 13-lactamases (ESBLs) [37]. 
Let us consider the last example in some detail. 
Most ESBLs are mutants of classical plasmid 
p-lactamases, such as TEM-1, but with one to four 
amino acid sequence substitutions [l]. These change 
the shape of the active site and extend the enzyme's 
spectrum, allowing attack on third-generation cephalo- 
sporins. Such mutant enzymes are increasingly 
prevalent; in a recent survey of klebsiellae from 
intensive care units in Western Europe, we found 
ESBLs in 23% of isolates [38]. Many TEM-derived 
ESBLs apparently only give a low level of resistance in 
vitro under standard test conditions, with low inocula 
(lo4-lo5 CFU). This is exemplified in Table 3 for a 
Klebsiella pneumoniae strain with TEM-26 p-lactamase. 
The organism showed a high level of cefiazidime 
resistance, but the MICs of other third- and fourth- 
generation cephalosporins remained below the then 
NCCLS breakpoints of 8-16 mg/L [39]. However, 
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when the inoculum was raised to lo7 CFU, the 
MICs of cephalosporins increased, whereas those of 
carbapenems were much less affected [37]. 
What do such inoculum effects signie? To answer 
this question, Rice et a1 [37] set up an intra-abdominal 
abscess infection model in rats with the TEM-26 
producer and adrmnistered antibiotics as continuous 
infusions. Except with cefiazidime, the drugs achieved 
serum concentrations well above the MICs observed 
for standard inocula. Three days into treatment they 
killed the rats and counted the number of bacteria per 
mL of abscess fluid. Despite their low MICs with 
standard inocula, cefotaxime, cefpirome and cefo- 
perazone achieved less than one log 10 reduction in the 
bacterial count (Table 3 ) .  In the case of cefoperazone, 
at least, killing was greatly increased if sulbactam 
was added, confirming the role of the 13-lactamase. 
Imipenem, which, like all carbapenems, has true 
stability to TEM-26 and other ESBLs, achieved a much 
better reduction in bacterial count. In short, the 
inoculum effect reflected (3-lactamase lability, and was 
predictive of clinical failure. 
CONCLUSION 
Theoretical considerations predict a close relationship 
between (3-lactamase quantity and the level of resistance 
to substrates, both with the extracellular enzymes of 
Gram-positive bacteria and with the periplasnlic types 
of Gram-negative organisms. Experimental data confirm 
these relationshps. This is seen most simply when a 
fi-lactamase is constitutive as, for example, with the 
TEM enzymes, where the MICs of substrates increased 
directly with enzyme quantity. Likewise, the amount of 
inhibitor required to potentiate substrates increased 
with the amount of enzyme. The situation is more 
complex with inducible (3-lactamases, because resistance 
also depends on the inducer power of the compound. 
Moreover, even if a compound is not an inducer, it 
may be prone to select mutants that hyperproduce 
the enzyme independently of induction. Turning to 
inhibitors, one must consider not only their ability 
to inactivate the enzyme but also their propensity 
to induce further enzyme synthesis. The final topic 
considered was that of inoculum effects and how these 
reflect 6-lactamase quantity In general, large inoculum 
effects for (3-lactams indicate 6-lactamase lability and 
clinical inadequacy, whether in Gram-positive or 
Gram-negative bacteria. 
DISCUSSION 
Professor Phillips: A number of lines of evidence 
suggest that S. aureus, which has an inducible enzyme, 
might have the equivalent of derepression. Things like 
amoxicillin-clavulanate resistance, the difference in 
range of zone sizes that you get. Is there anything 
known about that? 
Dr Livermore: When we were doing those studies I 
didn’t see any evidence of constitutive hyperproducers 
among staphylococci and I’m not aware of any good 
correlation between mode of p-lactamase expression 
and level of observed resistance in staphylococci. My 
feeling is that most, or all, p-lactams are good inducers 
of staphylococcal p-lactamases. I think it’s also true to 
say that one doesn’t have selection pressure working 
in quite the same way with a staphylococcus as one 
does with a Gram-negative rod. With Enterobacter 
the 6-lactamase is in the periplasm, hence if one 
cell happens to be derepressed-constitutive for the 
enzyme-it is resistant to cephalosporin challenge. This 
gives it an advantage over its fellows, and it’s selfish, so 
it’s going to overgrow. If a staphylococcus happens to 
be constitutive for its (3-lactamase, it’s pouring that 
6-lactamase out and helping its fellows as well as 
itself-it gets no individual advantage. If Staphylococcus 
is a socialist, then Enterobacter is very much a capitalist! 
Professor Phillips: There is resistance, say, to oxacillin 
or cloxacillin, which of course we don’t see very much 
because we test methicillin in the UK, which does 
suggest a greater amount of (3-lactamase. That’s not just 
inoculum is it? 
Dr Livermore: No, it’s not. I think that it is the 
amount of enzyme, but I’m not aware of any evidence 
that it reflects derepressed regulation. It may be that a 
huge total amount can be produced under induction. 
Professor Drusano: Can you enlighten us on the 
mechanism by which a-lactamase production is silent? 
Dr Livermore: I would assume it has something to do 
with the promoter sequence-that there isn’t a binding 
site for mRNA polymerase until the insertion sequence 
fits in. I don’t know the precise details, but I assume 
something along those lines. 
Professor Drusano: I was fascinated by the point 
where you had the basal expression of (J-lactamase, then 
the induced, and then the derepressed. Was the basal 
expression point-mutation insertional mutagenesis? 
Dr Livermore: No, it was a nitrosoguanadine mutant 
-but I’ve had 10 different mutants from 10 different 
strains, all showing absolutely the same patterns. I 
admit, though, that I can’t guarantee that there is not 
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some secondary mutation somewhere on the chromo- 
some. 
Professor Drusano: No, I understand that, but I also 
remember a paper you published a number of years ago 
[17] and it looked like carbapenems were 4-%fold 
more active against the (3-lactamase basal knock-out 
mutant whereas we’re only seeing that about two-fold 
here today. What’s more typical? 
Dr Livermore: It depends upon the species. For 
those Enterobacteriaceae that are normally AmpC 
inducible (Serratia, Enterobacter, Citrobacter) then a two- 
fold drop in MIC is typical. If we look at I? aeruginosa 
then you do see a slightly different pattern; where its 
enzyme is inducible or derepressed one would be 
looking at imipenem MICs of 2 mg/L. Knock out the 
enzyme, and the MIC comes down to 0.25 mg/L. 
Professor Drusano: And so is that (the difference 
between enterobacteria and Pseudornonas) due to the 
difference in penetration across the outer membranes 
interacting with the Michaeli-Menten kinetics? 
Dr Livermore: I believe so, but you know as well as 
I do that there are many questions about permeability 
in Pseudornonas that are only partly answered. In the case 
of meropenem, as I say, it has some ability to deactivate 
that (3-lactamase. So it’s very difficult to work out how 
much of the enzyme actually remains active under the 
meropenem challenge. What one sees there is that 
meropenem MICs for Pseudomonas are 0.25 or 0.5 
mg/L, irrespective of the mode of the AmpC enzyme 
production. 
References 
1. Bush K, Jacoby GA, Medeiros AA. A functional classi- 
fication for (3-lactamase and its correlation with niolecular 
structure. Antinicrob Agents Chemother 1995; 39: 121 1-33. 
2. Livermore DM. 6-Lactamases in laboratory and clinical 
resistance. Clin Microbiol Rev 1995; 8: 557-84. 
3. Hamilton-Mder JMT. Use of Michaelis-Menten kinetics in 
the analysis of synergism between 6-lactam antibiotics. 
J Theor Biol 1971; 31: 171-6. 
4. Hamilton-Mder JMT, Ranisay J. Synergism between 
6-lactam antibiotics: test of theoretical predictions made 
with Staphylococcus aureus. J Med Microbiol 1973; 6: 377-91. 
5. Zimmermann W, Rosselet A. Function of the outer 
membrane of Escherichia coli as a permeabhty barrier to beta- 
lactam antibiotics. Antimicrob Agents Chemother 1977; 12: 
6. Nikaido H, Normark S. Sensitivity of Escherichia coli to 
various 6-lactams is determined by the interplay of outer 
membrane permeability and degradation by periplasmic 
368-72. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14 
15. 
16 
17 
18 
19 
20 
21. 
6-lactaniases: a quantitative predictive treatment. Mol Micro- 
biol 1987; 1: 29-36. 
Sanders CC, Sanders WE. p-Lactam resistance in Gram- 
negative bacteria: global trends and clinical impact. Clin 
Infect Dis 1992; 15: 824-39. 
Livermore DM, Moosdeen F, Lindridge MA, Kho E’, 
Williams JD. Behaviour of TEM-1 p-lactamase as a resist- 
ance mechanism to niezlocdin, ampicillin and azlocillin in 
Escherichia coli. J Antimicrob Chemother 1986; 17: 139-46. 
Seetulsingh P, Hall LMC, Livermore DM. Activity of 
clavulanate combinations against TEM-1 (3-lactamase pro- 
ducing Escherichin coli isolates obtained in 1982 and 1989. 
J Antiniicrob Chemother 1991; 27: 749-59. 
Wu P-J, Shannon K, Phillips I. Effect of hyperproduction of 
TEM-1 p-lactamase on in vitro susceptibility of Escherichia 
coli to 6-lactam antibiotics. Antimicrob Agents Cheniother 
Shannon KF’, Williams H ,  King A, Phillips I .  Hyper- 
production of TEM-1 beta-lactamase in clinical isolates of 
Escherichia coli 015. FEMS Microbiol Lett 1990; 67: 319-24. 
Livermore DM, Seetulsingh P. Susceptibility of Escherichia 
coli isolates with TEM-1 (j-lactamase to combinations of 
BRL42715, tazobactam or clavulanate with piperacdin or 
amoxycdhn. J Antimicrob Cheniother 1991; 27: 761-7. 
Livermore DM. Activity of sulbactam combinations agamst 
Escherichia coli isolates with known amounts of TEM-1 
(j-lactamase. J Antimicrob Chemother 1992; 29: 219-32. 
French GL, Shannon W, Simmons N. Hospital outbreak of 
Klebsiella pneumoniae resistant to broad-spectrum cephalo- 
sporins and (j-lactam-(3-lactamase inhibitor combinations by 
hyperproduction of SHV-5 6-lactamase. J Clin Microbiol 
Akova M, Bonfiglio G, Livermore DM. Susceptibhty to 
(j-lactam antibiotics of mutant strains of Xanthomonas malto- 
philia with high- and low-level constitutive expression of L1 
and L2 6-lactamases. J Med Microbiol 1991; 35: 208-13. 
Mett H, Rosta S, Schacher B, Frei R. Outer membrane 
pernieabdity and (j-lactamase content in Pseudomonas malto- 
philia clinical isolates and laboratory mutants. Rev Infect Dis 
Livermore DM, Yang Y-J. 6-Lactamase lability and inducer 
power of newer 6-lactam antibiotics in relation to their 
activity against 6-lactamase inducibility mutants of Pseudo- 
monar aerngiuosa. J Infect Dis 1987; 155: 775-82. 
Yang Y-J, Livermore DM, Williams RJ. Chromosomal 
(j-lactaniase expression and antibiotic resistance in Entero- 
bacter cloacae. J Med Microbiol 1988; 25: 227-33. 
Yang Y, Livermore DM. Interactions of meropenem with 
Class I (j-lactamases. J Antimicrob Cheniother 1989; 23 
Chen HY, Livermore DM. Comparative in-vitro activity of 
biapenem against enterobacteria with P-lactamase-medated 
antibiotic resistance. J Antimicrob Chemother 1994; 33: 
Jacobs C, Huang LJ, Bartowsky E, Normark S, Part JL. 
Bacterial cell wall recycling provides cytosolic muropeptides 
as effectors for b-lactamase induction. EMBO J 1994; 13: 
4684-94. 
1994; 38: 494-8. 
1996; 34: 358-63. 
1988; 10: 765-9. 
(suppl A): 207-17. 
4 5 3 - 6 4. 
L i v e r m o r e :  P - L a c t a m a s e s :  q u a n t i t y  a n d  r e s i s t a n c e  4 5 1 9  
22. Livermore DM. Clinical significance of (J-lactamase induction 
and stable derepression in Gram-negative rods. Eur J Clin 
Microbiol 1987; 6: 439-45. 
23. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter 
bacteraeiiiia: clinical features and emergence of resistance 
during therapy. Ann Intern Med 1991; 115: 585-90. 
24. Tzelepi E, Tzouvelekis LS, Vatopoulos AC, Mentis AC, 
Tskaris A, Legalus NJ. High prevalence of stably derepressed 
class-I-fl-lactamase expression in multiresistant clinical isolates 
of Errterohacter cloacae from Greek hospitals. J Med Microbiol 
25. Burwen DR,  Banerjee SN, Gaynes RP, the National Noso- 
coinial Infection Surveillance System. Ceftazidime resistance 
amongst selected nosoconlial Gram-negative bacteria in the 
United States. J Infect Dis 1994; 170: 1622-5. 
26. Chen HY, Bonfiglio G, Allen M, et al. Multicentre survey 
of the in-vitro activity of piperacdhdtazobactam against 
bacteria from hospitalized patients in the British Isles. 
J Antiinicrob Cheniother 1993; 32: 247-66. 
27. Bonfiglio G, Livermore DM. p-Lactamase types amongst 
Staphylococcus aweus isolates in relation to susceptibility to 
(J-lactamase inhbitor combinations. J Antimicrob Chemother 
28. Bonfiglio G, Livermore DM. Behaviour of p-lactamase- 
positive and -negative Staphylococcus aureus isolates in 
susceptibility tests with piperacillin/tazobactam and other 
p-lactam/p-lactamase inhibitor combinations. J Antimicrob 
Chemother 1993; 32: 431-44. 
29. Akova M, Yang Y, Livermore DM. Interactions of tazobactani 
and clavulanate with inducibly and constitutively-expressed 
Class I (3-lactamases. J Antimicrob Chemother 1990; 25: 
30. Rasmussen BA, Bush K, Tally FP. Antimicrobial resistance 
in Bacteroides. Clin Infect Dis 1993; lh(supp1 4): S390-400. 
31. Podglajen I, Breuil J, Bordon F, Gutmanii L, Collatz E. A 
silent carbapeneniase gene in strains of Bacteroidesfragilis can 
be expressed after a one-step mutation. FEMS Microbiol 
Lett 1990; 91: 21-30. 
1992; 37: 91-5. 
1994; 33: 465-81. 
199-208. 
32. Podglajen I, B r e d  J, Collatz E. Insertion of a novel DNA 
sequence IS 1186, immedntely upstream of the silent carba- 
penemase gene &A, promotes expression of carbapeneni 
resistance in clinical isolates of Bacteroidcs j+a,@lis [abstract 
5871. In: Program and abstracts of the 33rd Interscience 
Conference on Antimicrobial Agents and Chemotherapy, 
New Orleans, Louisiana. Washington, DC: American Society 
for Microbiology, 1993. 
33. Senda K, Arakawa Y, Nakashinia K, et al. Multifocal 
outbreaks of metallo-fi-lactanrase producing Pseudomoms 
aevqiuosa resistant to broad-spectrum (3-lactanis, including 
carbapenems. Antiniicrob Agents Cheniother 1996; 40: 
549-53. 
34. Hadton-Miller JMT, Ranisay J. Stabhty of cephaloridme 
and cephalothin to staphylococcal penicillinase. J Gen 
Microbiol 1967; 49: 491-501. 
35. Ye0 SE Livermore DM. Effect of inoculum size on the in- 
vitro susceptibility to p-lactarn antibiotics of Moraxella 
cafarrhalis isolates with different fi-lactaniase types. J Med 
Microbiol 1994; 40: 252-5. 
36. Medeiros AA, O’Brien TF. Mechanisms of resistance to 
cephalosporins in ampicillin-resistant Eschwichia coli. J Infect 
Dis 1973; 128(suppl): S335-40. 
37. Rice LB, Yaou JDC, Klinm K, Eliopoulos GM, Moellering 
RC. Efficacy of different fi-lactanis against an extended- 
spectrum (J-lactamase-producing Mehsirlla pneumoninc in 
the rat intra-abdominal sepsis inodel. Antimicrob Agents 
Chemother 1991; 35: 1243-4. 
38. Liverinore DM, Yuan M. Antibiotic resistance and produc- 
tion of extended-spectrum (3-lactamases amongst Klehsiella 
spp. from intensive care units in Europe. J Antinucroh 
Chemother 1996; 38: 409-24. 
39. National Committee for Clinical Laboratory Standards. 
Minimum inhibitory concentration (MIC) interpretative 
standards for organisms other than Haemophilus, Neisscria 
gonorrhoene and Streptococcus pneumoiziae. M7-A3 (Aerobic 
Dilution). Vdanova, PA: National Conmiittee for Clinical 
Laboratory Standards, 1993. 
